Project Grant R41AI195240
Award Date 9/22/25
Completion Date 8/31/27
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01605, USA
Similar Awards
- This federal Project Grant award of $170,000 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports research by Prokaryotics Incorporated, a pharmaceutical and biotechnology company, to develop novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase enzyme MCD4. This research aims to address the critical...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), is funding the development of a novel antifungal agent that targets the cell wall biosynthesis pathway in pathogenic yeasts and molds. The $299,697 award to Prokaryotics Incorporated aims to identify lead compounds that demonstrate potent and broad-spectrum antifungal activity, lack cross-resistance to existing...
- The federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), aims to develop new antifungal agents targeting the fungal steryl-glucosidase (SGL1/SGLA) enzyme. The $782,178 award to The Research Foundation for The State University of New York, doing business as Stony Brook University, supports the following key efforts: High-throughput screening to identify chemical inhibitors of the fungal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Life Pharms Inc., a self-certified small disadvantaged business in Connecticut. The grant supports the development of a novel antifungal drug, LP10581, to combat drug-resistant fungal pathogens that cause invasive infections resulting in over 2.5 million deaths annually worldwide. The project aims to advance...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
- This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) aims to develop a novel class of small molecule antifungal therapeutics. The $300,616 award to Shy Therapeutics, LLC will fund research to identify and optimize new chemical structures with potent activity against drug-resistant fungal strains, including Cryptococcus neoformans and Candida auris. The 2-year...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
- This $750,815 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research conducted by the University of Maryland, Baltimore to investigate therapeutic targeting of the host hypoxia-response pathway to treat mucormycosis, a deadly invasive fungal infection. The research aims to explore alternative strategies beyond the currently limited treatment options for this disease, which has an unacceptably...
- This federal Project Grant award for $4,410,426 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to decipher the immunopathogenesis of mucormycosis (MCM) and use this knowledge to develop new diagnostic assays and approaches to therapy. The 5-year project, titled "DECIPHERING IMMUNOPATHOGENESIS OF MUCORMYCOSIS TO ADVANCE RISK STRATIFICATION, DIAGNOSIS AND MANAGEMENT OF THE DISEASE (MUCOR-ADVANCE)", is led by...